Background: Metabolic syndrome (obesity, glucose intolerance, insulin resistance and
dyslipidaemia) is a well-known adverse effect of most antipsychotics. It is particularly …

Clozapine causes obesity and type 2 diabetes (T2DM). Glucagon‐like peptide‐1 (GLP‐1)
receptor agonists (eg exenatide) can counter clozapine‐associated GLP‐1 dysregulation in …

Obesity is a common comorbidity in schizophrenia. Few studies have addressed obesity in
Chinese schizophrenia patients. The aims of this current study were to evaluate the …

Objectives: This study evaluated the effects of obesity on quality of life in schizophrenic
patients treated with atypical antipsychotics. Methods: The subjects were schizophrenic …

Background: Obesity is common in persons with schizophrenia. Besides its adverse health
effects, obesity reduces quality of life and contributes to the social stigma of schizophrenia …

Objectives The aims of this study were to examine the relationship between obesity and
psychopathology of inpatients with schizophrenia. Methods Eighty four inpatients with …

OBJECTIVE: The association of obesity, diabetes mellitus, drug compliance, and body
image with use of antipsychotic medication has been documented in many studies. We …

AIM To compare the prevalence of diabetes in patients with schizophrenia treated at a
community mental health center with controls in the same metropolitan area and to examine …

ObjectiveTo assess the prevalence of prediabetes and metabolic abnormalities among
overweight or obese clozapine-or olanzapine-treated schizophrenia patients, and to identify …